MINT Technologies

The MINT team develops technologies to treat complex GI and vascular conditions and has wide experience across different fields. Some technologies are now commercially available products while others are still under development and available for licensing.

Our Mission

MINT’s mission is to develop and bring to market medical devices and technology that will revolutionize the way minimally invasive surgery is performed- ultimately providing more efficient, effective treatment options for patients world-wide and at the same time reduce health care costs.

Learn more about the MINT Program.

Intellectual Property

MINT aggressively patents the technologies that we develop and has a robust patent portfolio across a range of projects. We currently have 16 issued patents (13 US, 3 international) and 35 pending patents (15 US, 20 international) across five major areas of focus.

See our Patents

Partnerships

The MINT program is defined by partnerships at every stage of the product development process. We work with a range of external advisors as we develop our technologies for license to entrepreneurs and investors. Once our technologies have been licensed we also continue to offer support through ongoing research alliances.

See our partnerships

FDA gives green light to MINT technology to treat colonic lesions

Building on the license they received from Cornell in 2014, Lumendi has secured FDA clearance for Dilumen (the MINT technology formally known as ESP).

Read full article

Sphere paper wins award

Research carried out in collaboration between MINT and University College London has won a prestigious award from the Journal of Cardiovascular Engineering Technologies (CVET).

Read full article